Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 8/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CCR6 | P51684 | 1/20 | 0.34 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.34 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9950395 | 0.81 | ALDH1A1 (0.50) | CTSLCTSBCTSK | |
| SCHEMBL9950324 | 0.81 | ALDH1A1 (0.50) | CTSLCTSBCTSK | |
| SCHEMBL1933158 | 0.67 | ALDH1A1 (0.54) | NPC1RAB9ACTSLCTSBCTSK | |
| SCHEMBL1933160 | 0.67 | ALDH1A1 (0.54) | NPC1RAB9ACTSLCTSBCTSK | |
| SCHEMBL12550927 | 0.66 | ALDH1A1 (0.47) | SIGMAR1CHRM5CHRM1LMNATMEM97 | |
| SCHEMBL3826174 | 0.65 | MEN1 (0.64) | SIGMAR1LMNATMEM97NPC1RAB9A | |
| SCHEMBL14370876 | 0.62 | ALDH1A1 (0.68) | CTSLCTSBCTSK | |
| SCHEMBL29460302 | 0.61 | CA1 (0.52) | LMNANPC1RAB9ASMN1; SMN2CTSL | |
| SCHEMBL27868751 | 0.61 | SIGMAR1 (0.57) | CCR5SIGMAR1CHRM2CHRM5CHRM1 | |
| SCHEMBL27868750 | 0.61 | SIGMAR1 (0.57) | CCR5SIGMAR1CHRM2CHRM5CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120289501-A1 | Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls | NOVARTIS AG (CH) | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289501-A1 | Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls | CYP1B1, CYP11B2, CCNI | CCR5 2046/4885SIGMAR1 2691/4885CHRM2 3959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.